571 Results (Page 2 of 23)
UK Markets Research Reports
UK Antibacterial (Antibiotics) Drugs Market Analysis
UK Antibacterial (Antibiotics) Drugs Market is at around $1.32 Bn in 2023 and is projected to reach $1.54 Bn in 2030, exhibiting a CAGR of 2.2% during the forecast period. The market is growing due to factors such as the aging population, rising prevalence of infectious diseases, and technological advancements. The market is dominated by key players like Wockhardt UK Ltd, Teva Pharmaceuticals Industries Ltd, AstraZeneca plc, Pfizer Inc., Roche, Novartis AG, GlaxoSmithKline plc, Abbott Laboratories, Johnson & Johnson, Merck & Co., Inc., and Sanofi S.A.
UK Myelodysplastic Syndrome (MDS) Therapeutics Market Analysis
UK Myelodysplastic Syndrome (MDS) therapeutics market is projected to grow from $59 Mn in 2022 to $102.9 Mn by 2030, registering a CAGR of 7.2% during the forecast period of 2022-30. The market for pharmaceuticals for myelodysplastic syndrome (MDS) is growing as a result of a number of factors, including a rise in pediatric population, improved awareness, the launch of novel drugs, government initiatives to provide target-specific therapy, and favourable reimbursement policies. Major global players in this market are Abbott, Boehringer Ingelheim International GmbH, Johnson & Johnson Private Limited, MEI Pharma Inc., MTW Endoskopie Manufaktur, Aprea Therapeutics, Dr. Reddy's Laboratories Ltd, AbbVie Inc., Acceleron Pharma, Inc., Mylan N.V., Bristol-Myers Squibb Company, Eisai Co., Ltd., and LGM Pharma are a few other companies that are involved in the pharmaceutical industry.
UK ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis
The UK Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market is projected to grow from $769 Mn in 2022 to $1,179 Mn in 2030 with a CAGR of 5.5% for the year 2022-30 as there is an increase in awareness in the diagnosis and treatment for ADHD as well as availability of new therapeutic options in UK. The UK ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Colonis Pharma, Shire, and Advanz Pharmaceuticals are the key players in the market.
UK Chronic Lymphocytic Leukemia Therapeutics Market Analysis
UK Chronic Lymphocytic Leukemia Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A typical form of adult Leukemia known as chronic lymphocytic Leukemia (CLL) is characterized by an excessive production of aberrant white blood cells. In most cases, it happens when the bone marrow generates damaged cells, which interfere with the formation of antibodies and eventually render them ineffective against infections. The rise in chronic lymphocytic Leukemia cases is anticipated to fuel market expansion throughout the anticipated time frame. The market will rise as a result of the various treatment options available and the familial history of chronic lymphocytic leukemia. The high cost of treatment, however, is anticipated to limit market expansion. AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Exelixis, Inc., Bristol-Myers Squibb Company, Novartis AG, Johnson & Johnson Services, Inc., AbbVie Inc., MorphoSys AG, Ono Pharmaceutical Co., Ltd., and Amgen, Inc. are a few of the leading companies profiled in the chronic lymphocytic leukemia therapeutics market report.
UK Virtual Clinical Trials Market Analysis
This report presents a strategic analysis of the UK Virtual Clinical Trials Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the UK Virtual Clinical Trials Market, offering unmatched value, accuracy and expert insights.
UK Growth Hormone Deficiency Clinical Trials Market Analysis
This report presents a strategic analysis of the UK Growth Hormone Deficiency Clinical Trials Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the UK Growth Hormone Deficiency Clinical Trials Market, offering unmatched value, accuracy and expert insights.
UK COVID-19 Clinical Trials Market Analysis
This report presents a strategic analysis of the UK COVID-19 Clinical Trials Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the UK COVID-19 Clinical Trials Market, offering unmatched value, accuracy and expert insights.
UK Clinical Trials Support Service Market Analysis
This report presents a strategic analysis of the UK Clinical Trials Support Service Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the UK Clinical Trials Support Service Market, offering unmatched value, accuracy and expert insights.
UK Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market Analysis
This report presents a strategic analysis of the UK Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the UK Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market, offering unmatched value, accuracy and expert insights.
UK Nutritional Supplements Market Analysis
By 2030, it is anticipated that the UK Nutrition and Supplements market will reach a value of $16.42 Bn from $9.92 Bn in 2022, growing at a CAGR of 6.5% during 2022-2030. The market is primarily dominated by local players such as GNC, The Protein Works, Holland & Barrett, and Nestle Nutritionals. The market for nutrition and supplements in the UK is primarily driven by reimbursement scenarios, increasing customer awareness, and strict government regulations. The UK nutrition and supplements market in the UK is segmented by Type, Product, application, and Distribution Channel.
UK Conjunctivitis Therapeutics Market Analysis
The UK Conjunctivitis Therapeutics Market was valued at $107 Mn in 2022 and is predicted to grow at a CAGR of 3.4% from 2023 to 2030, to $139 Mn by 2030. The key drivers of this industry include the surging prevalence of conjunctivitis, expanding product offerings in the industry, and high unmet medical needs. The industry is primarily dominated by players such as Allergan, Bausch & Lomb, Sirion, Akorn, Novartis, Sanofi, Auven, and Ocular among others.
UK Artificial Intelligence (AI) in Healthcare Market Analysis
The UK Artificial Intelligence (AI) In Healthcare Market is projected to grow from $0.18 Bn in 2022 to $3.18 Bn by 2030, registering a CAGR of 43.22% during the forecast period of 2022-2030. The market will be driven by. The market is segmented by healthcare components & by healthcare applications. Some of the major players include NVIDIA Corporation, GE Healthcare & Google DeepMind Health.
UK Chronic Inflammatory Demyelinating Polyneuritis Therapeutics Market Analysis
UK Chronic Inflammatory Demyelinating Polyneuritis Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A acquired immune-mediated neuropathy that affects peripheral nerves and nerve roots, chronic inflammatory demyelinating polyneuropathy (CIDP; also known as chronic inflammatory demyelinating polyradiculoneuropathy) is characterised by a progressive or relapsing-remitting course of symmetric weakness of the proximal and distal muscles. Growing government spending and disease awareness have been the market's main drivers for Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics. Bio products laboratory Ltd., Momenta Pharmaceuticals, Grifols, Baxter, Octapharma, Shire, Kedrion SPA, Misubishi Tanabe Pharma Corporation, CSL Behring, and Teijin Pharma Ltd. are global firms in the Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics market.
UK Primary Biliary Cholangitis (PBC) Therapeutics Market Analysis
UK Primary Biliary Cholangitis (PBC) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Due to a variety of critical variables, including growing public awareness of rare diseases, improving healthcare infrastructure, high disposable income, and government backing for cutting-edge autoimmune disease treatments, the market for primary biliary cholangitis treatments is booming.Major global players in Primary Biliary Cholangitis (PBC) Therapeutics Market are Actavis, Inc.; Epic Pharma, LLC; Mylan Pharmaceuticals, Inc.; Teva Pharmaceuticals; Glenmark Pharmaceuticals, Ltd.; Par Pharmaceutical, Inc.; Intercept Pharmaceuticals, Inc
UK Vitamin and Minerals Market Analysis
This report presents a strategic analysis of the UK Vitamin and Minerals Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the UK Vitamin and Minerals Market, offering unmatched value, accuracy and expert insights.
UK Women's Health Market Analysis
In the UK, the National Health Service (NHS) provides free medical care to women, as a result, the market size of UK women’s health is predicted to witness an upsurge of about $537 Mn in 2022 with a CAGR of 5.5% and is estimated to reach $824 Mn in 2030. Growing female labour force participation, particularly in the UK, has made a substantial contribution to the market's expansion. The market is segmented by product type and by disease type. Amgen, Allergen, and Merck and Co. are some of the leading players in the women’s health market.
UK Oral Care Market Analysis
The UK oral care market was valued at $916 Mn in 2022 and is estimated to expand at a CAGR of 4.2% from 2022 to 2030 and will reach $1273 Mn in 2030. One of the main reasons propelling the growth of this market is Rising Demand for Cosmetic Dentistry, Technological Advancements. The market is segmented by type, drug, and distribution channel. Some key players in this market are Wisdom Toothbrushes, Curaprox UK, Oralieve, DenTek, Lush UltraDEX, and Waken.
UK Cholesterol Therapeutics Market Analysis
The UK Cholesterol Therapeutics Market is anticipated to experience a growth from $631.8 Mn in 2022 to $662.8 Mn by 2030, with a CAGR of 0.6% during the forecast period of 2022-2030. The increasing prevalence of high cholesterol, alignment with NHS policies emphasizing cost-effectiveness, and the demand for innovative solutions collectively act as drivers propelling the growth of the UK market. The UK Cholesterol Therapeutics Market encompasses various players across different segments such as Pfizer, Merck, Roche, Novartis, Amgen, AstraZeneca, Hikma Pharmaceuticals, Wockhardt, Alvotec, Omega Pharma, etc., among various others.
UK Central Nervous System (CNS) Therapeutics Market Analysis
The UK Central Nervous System (CNS)Therapeutics Market was valued at $5.460 Bn in 2022 and is predicted to grow at a CAGR of 4.4% from 2023 to 2030, to $7.705 Bn by 2030. The key drivers of this industry include the surge in the prevalence of CNS disorders, increased healthcare expenditure, and supportive government initiatives. The industry is primarily dominated by players such as AbbVie, Pfizer, Eli Lilly, Teva, Biogen, and Novartis among others.
UK Over The Counter (OTC) Analgesics Market Analysis
This report presents a strategic analysis of the UK Over The Counter (OTC) Analgesics Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the UK Over The Counter (OTC) Analgesics Market, offering unmatched value, accuracy and expert insights.
UK Telemedicine Market Analysis
The UK telemedicine market size was valued at $1.58 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.25% from 2022 to 2030 and will reach $16.2 Bn in 2030. The market is driven by factors such as the increasing adoption of digital health solutions and the growing prevalence of chronic diseases. The market is segmented by Component Type, Application Type, Modality Type, and Delivery Mode Type. The major players in the UK telemedicine market are Babylon Health (UK), Medicspot (UK), Doctor Care Anywhere (UK), Push Doctor (UK), Live Doctor (UK), Doctor on Demand, and others.
UK Electronic Health Records Market Analysis
The UK electronic health record market size was valued at $736 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 2% from 2022 to 2030 and will reach $862 Mn in 2030. This growth can be attributed to Technological advancements in healthcare offering a promising future for enhancing healthcare delivery through electronic health records. The market is segmented by product type, application type, and end user. Some of the major players are Cerner Healthcare, InPS, System C & Graphnet Health, TPP, and others.
UK Digital Health Market Analysis
The UK Digital Health market is projected to grow from $5.49 Bn in 2022 to $18.74 Bn by 2030, registering a CAGR of 16.6% during the forecast period of 2022-30. Higher healthcare funding by the government and growing investments by innovative start-up companies across the UK are the major drivers for the digital health market. The market is segmented by solution, by deployment & by end-use. Some of the major players include Huma, CERA CARE & Cerner Corporation.
UK Home Healthcare Market Analysis
UK's home healthcare market is projected to grow from $9.429 Bn in 2022 to $14.494 Bn by 2030, registering a CAGR of 5.93% during the forecast period of 2022-30. The demand for home healthcare systems in the UK has been significantly impacted by the rising prevalence of chronic diseases. One of the main reasons for the expansion of the UK home healthcare business has been the rise in mergers and acquisitions. Some key players in the UK home healthcare market include Bupa, Care UK, Barchester Healthcare, Four Seasons Health Care, and HC-One.
UK Physiotherapy Market Analysis
The UK physiotherapy market size was valued at $1.38 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 3.85% from 2022 to 2030 and will reach $1.87 Bn in 2030. The UK physiotherapy market is expected to grow due to an increase in the number of people suffering from chronic conditions as well as an ageing population. The market is segmented by Product Type, Application Type, and End User. The major players in the UK physiotherapy market are Machine Medicine, PneumaCare, Qured, Action First Physiotherapy Ltd, and others.
